Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02252198 · ClinicalTrials.gov registry record
Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 504
- Enrollment target
NCT02252198: Completed study, sponsored by Johns Hopkins University.
NCT02252198 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 504 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02252198 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 504 participants
- Enrollment target
Study Summary
Assess sensitivity and specificity of two nucleic acid amplification tests, namely Epistem Genedrive® and MolbioTruenat™ in raw sputum compared to the WHO-endorsed GeneXpert® MTB/RIF assay using a gold standard of four cultures
Interventions
- OTHER Epistem Genedrive® and MolBio Truenat™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 504 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02252198
The ClinicalTrials.gov registry entry for NCT02252198 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epistem Genedrive® and MolBio Truenat™ is the first listed.
NCT02252198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02252198 about?
NCT02252198 is a clinical study titled "Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests". Assess sensitivity and specificity of two nucleic acid amplification tests, namely Epistem Genedrive® and MolbioTruenat™ in raw sputum compared to the WHO-endorsed GeneXpert® MTB/RIF assay using a gold standard of four cultures
What is the current status of trial NCT02252198?
This trial is currently completed. The enrollment target is 504 participants. The study started on 2014-02. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02252198?
The interventions under investigation include: Epistem Genedrive® and MolBio Truenat™ (OTHER).
Who is sponsoring clinical trial NCT02252198?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.